Marketplace · Netherlands
Pharmacies businesses in Maastricht typically transact at 5.2x–7.8x EV/EBITDA, with a sector median of 6.4x in the Netherlands. Limburg capital at the German-Belgian border.
Maastricht (population ~120,000, Limburg) anchors pharmacies transactions at a 6.4x EV/EBITDA median, with most defensible deals landing between 5.2x (conservative) and 7.8x (strong recurring revenue). Limburg capital at the German-Belgian border. SMEs span life sciences, hospitality, cross-border services and professional firms; the tri-border location widens the buyer pool into Germany and Belgium.
Upswitch is anonymity-by-design — new pharmacies dossiers in Maastricht surface here as soon as they pass advisor validation. Subscribe to the alert and we'll notify you within hours of the next listing going live.
Browse all listingsFor a pharmacies SME in Maastricht with normalised EBITDA above €200k, expect the headline price to anchor on a 6.4x EV/EBITDA multiple, with a working-capital peg, 5–15% escrow, and (in 35–45% of deals) an earn-out tied to year-one EBITDA or customer retention. Cross-border buyer interest from Belgian acquirers is consistently elevated.
Limburg capital at the German-Belgian border. SMEs span life sciences, hospitality, cross-border services and professional firms; the tri-border location widens the buyer pool into Germany and Belgium. For pharmacies specifically, Maastricht's buyer pool typically includes regional family businesses, Benelux-wide strategic acquirers, and (for deals above ~€2m EV) PE-backed roll-up platforms.
